.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has decided on Eli Lilly (NYSE: LLY) as its top biopharma selection for 2025 and also measured an additional nine titles in the space as over weight. The assets financial institution said in a keep in mind that it remains to feel “diabesity is actually readied to become.